Forward Ventures appeared to be the VC, which was created in 1993. The leading representative office of defined VC is situated in the San Diego. The company was established in North America in United States.
The fund was created by Standish M. Fleming. The overall number of key employees were 2.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Forward Ventures, startups are often financed by Domain Associates, Gimv, Alta Partners. The meaningful sponsors for the fund in investment in the same round are Alta Partners, Gimv, Roche Venture Fund. In the next rounds fund is usually obtained by Alta Partners, Gimv, Domain Associates.
Comparing to the other companies, this Forward Ventures performs on 3 percentage points less the average number of lead investments. The high activity for fund was in 2007. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 10 - 50 millions dollars. When the investment is from Forward Ventures the average startup value is 10-50 millions dollars. Speaking about the real fund results, this VC is 9 percentage points less often commits exit comparing to other organizations. The increased amount of exits for fund were in 2007. The fund is constantly included in 2-6 deals per year.
The fund has exact preference in a number of founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline Tioga Pharmaceuticals, Viracta Therapeutics, Affinium Pharmaceuticals Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular fund investment industries, there are Biopharma, Medical Device. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
Related Funds
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Xanadu | $100M | 09 Nov 2022 | Old Toronto, Ontario, Canada | ||
TO THE MARKET | $5M | 05 Oct 2021 | New York, New York, United States | ||
SpotQA | $3M | 20 Aug 2019 | London, England, United Kingdom | ||
Viracta Therapeutics | $18M | 04 Apr 2017 | California, United States | ||
Syndax Pharmaceuticals | $80M | 24 Aug 2015 | Massachusetts, United States | ||
Syndax Pharmaceuticals | $26M | 27 Aug 2013 | Massachusetts, United States | ||
Viracta Therapeutics | $13M | 12 Mar 2012 | California, United States | ||
Affinium Pharmaceuticals | $15M | 29 Aug 2011 | Austin, Texas, United States | ||
Viracta Therapeutics | $12M | 21 Apr 2010 | California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Xanadu | $100M | 09 Nov 2022 | Old Toronto, Ontario, Canada | ||
TO THE MARKET | $5M | 05 Oct 2021 | New York, New York, United States | ||
SpotQA | $3M | 20 Aug 2019 | London, England, United Kingdom | ||
Viracta Therapeutics | $18M | 04 Apr 2017 | California, United States | ||
Syndax Pharmaceuticals | $80M | 24 Aug 2015 | Massachusetts, United States | ||
Syndax Pharmaceuticals | $26M | 27 Aug 2013 | Massachusetts, United States | ||
Viracta Therapeutics | $13M | 12 Mar 2012 | California, United States | ||
Affinium Pharmaceuticals | $15M | 29 Aug 2011 | Austin, Texas, United States | ||
Viracta Therapeutics | $12M | 21 Apr 2010 | California, United States |